Highlights Pharnext SCA

Equities

ALPHA

FR001400N1P4

Market Closed - Euronext Paris Other stock markets 11:35:00 2024-04-26 am EDT			5-day change	1st Jan Change
0.1499 ^EUR	-8.88%		-12.75%	-92.50%

Apr. 25	Pharnext: share price rises on encouraging comments	CF
Mar. 06	Pharnext: listing suspended pending further update	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pharnext: share price rises on encouraging comments	Apr. 25	CF
Pharnext: listing suspended pending further update	Mar. 06	CF
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...	Feb. 21
Pharnext launches drastic cost-cutting plan	Jan. 17	CF
Pharnext Delays Exclusivity Agreement for Peripheral Nerve Disease Drug; Shares Sink	Nov. 27	MT
Pharnext Manufactures US Registration Batches of Oral Solution Ahead of FDA Application	Nov. 20	MT
Pharnext SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-30	CI
Pharnext Shares Soar on EUR510 Million Offer for Neuropathy Drug Candidate	23-10-30	MT
Pharnext Shares Surge Amid EUR250 Million Offers for Main Drug Candidate	23-10-16	MT
Pharnext SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Pharnext Soars 63% on Increased Funding Commitment of Néovacs	22-12-28	MT
Pharnext Strengthens Its Ties with Néovacs to Secure the Next Steps in Its Development	22-12-28	CI
Pharnext SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-17	CI
Pharnext SA Announces the Publication of Symptom Burden Findings of Charcot-Marie-Tooth Disease Type1a ("Cmt1a") from the ‘Real-World' Digital Lifestyle Study, CMT&Me, in the Journal of Clinical Neuromuscular Disease	22-09-14	CI
Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial	22-09-12	CI
Pharnext Soars 13% On Potential $20 Million Investment From Neovacs	22-08-08	MT
Pharnext Secures $13 Million Loan To Pay Down Existing Debt	22-06-08	MT
Pharnext Announces New Results from the Ongoing Open-Label Follow-Up Extension Study of PXT3003	22-05-16	CI
Pharnext SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Pharnext SA Announces New Results from an Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A	21-04-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Pharnext SCA

Equities

ALPHA

FR001400N1P4

Highlights

Filters